Tinlarebant
Tinlarebant is an oral, once-daily RBP4 antagonist designed to reduce the retinal accumulation of toxic vitamin-A byproducts. It is Belite Bio's lead candidate for Stargardt disease and geographic atrophy.
Also known as: LBS-008
Tinlarebant forecasting benchmarks
1 benchmarkMechanism & molecular targets
Indications studied
Developed by
About Tinlarebant
What is Tinlarebant?
Tinlarebant is an oral, once-daily RBP4 antagonist designed to reduce the retinal accumulation of toxic vitamin-A byproducts. It is Belite Bio's lead candidate for Stargardt disease and geographic atrophy. It is a oral small molecule (rbp4 antagonist) developed by Belite Bio.
What does Tinlarebant target?
Tinlarebant acts on Retinol-binding protein 4 (RBP4).
How well do AI models predict Tinlarebant trial outcomes?
Open any benchmark below to see the full model leaderboard scored by accuracy, Brier score, and log loss. Models forecast each readout before it is public, so the scores reflect genuine predictive skill rather than hindsight.